Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial

Category Primary study
ConferenceCOSA's 51st Annual Scientific Meeting
Year 2024
This article has no abstract
Epistemonikos ID: 08520296406f6d530e9512290dc966db03429a0f
First added on: Jan 10, 2026